Wang, X., Christiani, D.C., Mark, E.J., et al. (1999) Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma. Cancer, 85, 1734-1739. doi:10.1002/(SICI)1097-0142(19990415)85:8<1734::AID-CNCR13>3.0.CO;2-1

has been cited by the following article:

• TITLE: Discordant tumor response in the treatment of ALK-rearranged non-small cell lung cancer leads to the diagnosis of synchronous multiple primary lung cancer

  AUTHORS: Benny Johnson, Maged Khalil

  KEYWORDS: Non-Small Cell Lung Cancer; Crizotinib; Synchronous Multiple Primary Lung Cancer; EML4-ALK Fusion Gene

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.2 No.1, March 12, 2013

  ABSTRACT: The advent of targeted molecular therapy against the EML4-ALK fusion gene is the latest therapeutic intervention for a subset of patients with non-small cell lung cancer (NSCLC). Crizotinib (Xalkori) is an orally available small molecule tyrosine kinase inhibitor proven in clinical trials to significantly impact progression free survival and overall response rate. We present a case of a 56-year-old male with NSCLC whose lack of a positive treatment response to this therapy led to the clinical suspicion and identification of the underdiagnosed entity known as synchronous multiple primary lung cancer (SMPLC).